The article discusses the use of statins in preventing cardiovascular disease, emphasizing their significant reduction in ischemic heart disease (IHD) events (61%) and stroke (17%). The potential increase in hemorrhagic stroke is considered minimal compared to the overall protective effects. The authors thank several contributors for unpublished data from trials and acknowledge Leo Kinden for comments on the manuscript. They also disclose competing interests, including a patent application for a combined pill to reduce four cardiovascular risk factors. The second part of the article focuses on the value of low-dose combination treatment with blood pressure-lowering drugs. The study meta-analyzed 354 randomized, double-blind, placebo-controlled trials of five main categories of blood pressure-lowering drugs: thiazides, β-blockers, ACE inhibitors, angiotensin II receptor antagonists, and calcium channel blockers. The results show that all five categories produced similar reductions in blood pressure, with the average reduction being 9.1 mm Hg systolic and 5.5 mm Hg diastolic at standard dose, and 7.1 mm Hg systolic and 4.4 mm Hg diastolic at half standard dose. The blood pressure-lowering effects were additive across different drug categories, and the prevalence of adverse effects was lower at half standard dose. The study concludes that combination low-dose drug treatment increases efficacy and reduces adverse effects, suggesting that using three drugs at half standard dose could reduce the risk of stroke by 63% and IHD events by 46% in individuals aged 60-69.The article discusses the use of statins in preventing cardiovascular disease, emphasizing their significant reduction in ischemic heart disease (IHD) events (61%) and stroke (17%). The potential increase in hemorrhagic stroke is considered minimal compared to the overall protective effects. The authors thank several contributors for unpublished data from trials and acknowledge Leo Kinden for comments on the manuscript. They also disclose competing interests, including a patent application for a combined pill to reduce four cardiovascular risk factors. The second part of the article focuses on the value of low-dose combination treatment with blood pressure-lowering drugs. The study meta-analyzed 354 randomized, double-blind, placebo-controlled trials of five main categories of blood pressure-lowering drugs: thiazides, β-blockers, ACE inhibitors, angiotensin II receptor antagonists, and calcium channel blockers. The results show that all five categories produced similar reductions in blood pressure, with the average reduction being 9.1 mm Hg systolic and 5.5 mm Hg diastolic at standard dose, and 7.1 mm Hg systolic and 4.4 mm Hg diastolic at half standard dose. The blood pressure-lowering effects were additive across different drug categories, and the prevalence of adverse effects was lower at half standard dose. The study concludes that combination low-dose drug treatment increases efficacy and reduces adverse effects, suggesting that using three drugs at half standard dose could reduce the risk of stroke by 63% and IHD events by 46% in individuals aged 60-69.